Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $18.4 million.

  • Xeris Biopharma Holdings' Free Cash Flow rose 32193.86% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 13353.34%. This contributed to the annual value of -$37.0 million for FY2024, which is 2135.55% up from last year.
  • Xeris Biopharma Holdings' Free Cash Flow amounted to $18.4 million in Q3 2025, which was up 32193.86% from $182000.0 recorded in Q2 2025.
  • Xeris Biopharma Holdings' Free Cash Flow's 5-year high stood at $18.4 million during Q3 2025, with a 5-year trough of -$48.4 million in Q1 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' median Free Cash Flow value was -$16.1 million (recorded in 2022), while the average stood at -$14.4 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Free Cash Flow plummeted by 16209.66% in 2021, and later surged by 32193.86% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Free Cash Flow (Quarter) stood at -$29.1 million in 2021, then soared by 44.56% to -$16.1 million in 2022, then surged by 146.35% to $7.5 million in 2023, then crashed by 73.56% to $2.0 million in 2024, then soared by 833.27% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $182000.0 for Q2 2025, and -$10.0 million during Q1 2025.